WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET.
A live webcast of the event will be available on the Investor section of the Company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT:CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos Therapeutics routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos Therapeutics.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$10.15 |
| Daily Volume: | 0 |
| Market Cap: | US$448.730M |
April 28, 2025 March 05, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
